Goldman Sachs Maintains Buy on Arcus Biosciences, Raises Price Target to $34
Arcus Biosciences, Inc.
Arcus Biosciences, Inc. RCUS | 0.00 |
Goldman Sachs analyst Richard Law maintains Arcus Biosciences (NYSE:
RCUS) with a Buy and raises the price target from $30 to $34.